Skip to main content

Virpax shares rise on expanded licensing deal for experimental drug

The new drug candidate showed effectives against influenza and SARS-CoV-2 in preclinical studies.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.